Aduhelm demonstrated a consistent treatment effect for slowing decline in cognitive, functional and behavioral domains among patients with early Alzheimer’s disease in item-level analysis of the phase 3 EMERGE study. Results from this analysis demonstrated consistency with results from the primary analysis of clinical endpoints for Aduhelm (aducanumab, Biogen/Eisai), according to the study results. Researchers […]

Jim Joyce is the Co-Founder, Chairman, and CEO of Sigyn Therapeutics, and we talk about removing inflammatory targets from the bloodstream with advanced blood purification technology. Jim says, “The next transformative step in the recipe of blood purification is the advancement of devices that can address the sources of inflammation, which could be a viral or […]

COVID-19-Related Mesoblast Limited presented 90-day survival outcomes from the 222-patient trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS). The data demonstrated that two doses of the drug at days 3-5 provided durable survival benefit through at least 90 days in the subgroup of patients under 65 years of age. RedHill Biopharma announced that […]